Stock Market Reviews

EVO (Evotec SE) News

Get the latest news, insights, and market updates on EVO (Evotec SE). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• [Latest] Global Induced Pluripotent Stem Cells Production Market Size/Share Worth USD 4.34 Billion by 2034 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
  [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Induced Pluripotent Stem Cells Production Market size & share revenue was valued at approximately USD 1.75 Billion in 2024 and is expected to reach USD 1.92 Billion in 2025 and is expected to reach around USD 4.34 Billion by 2034, at a CAGR of 9.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Lonza,
  Aug 21, 2025 - $EVO
• Drug Discovery Services Company Evaluation Report 2025 | LabCorp, Evotec, and Selvita Lead with Comprehensive Research and Laboratory Services
  The Drug Discovery Services Companies Quadrant provides an in-depth analysis of the drug discovery services market, highlighting key players, technological advancements, and trends. Conducted by MarketsandMarkets 360 Quadrants, over 150 companies were evaluated, recognizing the Top 25 as leaders in the industry. Contract Research Organizations (CROs) offer extensive services such as hit identification and hit-to-lead optimization. Market growth is fueled by increased R&D investments, a growing d
  Aug 14, 2025 - $EVO
• Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
  Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect ...
  Aug 13, 2025 - $EVO
• Evotec SE to announce first half-year results 2025 on 13 August 2025
  HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, ...
  Aug 6, 2025 - $EVO
• Sandoz bolsters in-house biosimilar manufacturing with Evotec acquisition
  The generics specialist will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant for $300m.
  Aug 4, 2025 - $EVO
• Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Rate Decision
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad
  Jul 30, 2025 - $EVO
• Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
  HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) ...
  Jul 30, 2025 - $EVO